Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops

Benzinga_recent_news01-27

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606207563?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/27/Stuttgart--Germany---04-21-2023-Person-H.jpeg?optimize=medium&dpr=2&auto=webp&width=120","is_english":true,"pubTime":"2026-01-27 17:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606207563","market":"us","top_or_hot":-1,"title":"Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops","media":"Benzinga_recent_news","content":"<div>\n<p>Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/01/50148730/cathie-woods-favorite-biotech-stock-is-under-pressure-amid-insider-sales-and-slow-revenue-growth-momentum-score-drops\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-27 17:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/biotech/26/01/50148730/cathie-woods-favorite-biotech-stock-is-under-pressure-amid-insider-sales-and-slow-revenue-growth-momentum-score-drops><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/01/50148730/cathie-woods-favorite-biotech-stock-is-under-pressure-amid-insider-sales-and-slow-revenue-growth-momentum-score-drops\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.benzinga.com/markets/biotech/26/01/50148730/cathie-woods-favorite-biotech-stock-is-under-pressure-amid-insider-sales-and-slow-revenue-growth-momentum-score-drops","article_id":"2606207563","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/27/Stuttgart--Germany---04-21-2023-Person-H.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/01/50148730/cathie-woods-favorite-biotech-stock-is-under-pressure-amid-insider-sales-and-slow-revenue-growth-momentum-score-drops","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606207563","pubTimestamp":1769506380,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","ARKK":"ARK Innovation ETF"},"translate_title":"凯西·伍德(Cathie Wood)最喜欢的生物科技股因内幕销售和收入增长缓慢而面临压力：动量得分下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKK":1.5,"LABU":1.5},"content_text":"Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.\nThe company, which often features at the top of several funds managed by Cathie Wood’s Ark Invest, such as the Ark Innovation ETF (BATS:ARKK) and the Ark Genomic Revolution ETF (BATS:ARKG), is seeing its Momentum score slide over the past couple of days.\nThe Momentum score in Benzinga’s Edge Stock Rankings is calculated based on the strength of a stock, taking into consideration its price movements and volatility across multiple time frames, before being ranked as a percentile against others.\nCRISPR Therapeutics AG has seen its Momentum score drop from 76.81 to 50.97 within the span of a week, as the stock itself plunged over 10% since last week. \nThe most immediate trigger for the pullback appears to be a pre-arranged share sale by CEO Samarth Kulkarni, who sold more than 90,000 shares over three days last week. \nWhile the transactions were executed under a previously disclosed trading plan and Kulkarni still retains a sizable stake of roughly 85,000 shares, the scale and timing of the sales nonetheless unsettled investors.\nThis comes alongside its slow pace of revenue growth, which stood at just $890,000 during its third-quarter results, falling significantly short of consensus estimates at $8.06 million, which further spooked investors, leading to a loss of confidence in the stock.\nThe stock scores poorly in Benzinga’s Edge Stock Rankings, with an unfavorable price trend in the short and medium terms. \nImage via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606207563","isCrawlerRequest":true}